Per Lundkvist

Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study

Jan W. Eriksson, Per Lundkvist, Per‐Anders Jansson et al. · Diabetologia · 2018 · 387 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

FKBP5 expression in human adipose tissue: potential role in glucose and lipid metabolism, adipogenesis and type 2 diabetes

Cherno O. Sidibeh, Maria J. Pereira, Xesús M. Abalo et al. · Endocrine · 2018 · 120 citations · Full text

Life Sciences, Endocrinology, Molecular Biology +17

Dapagliflozin once‐daily and exenatide once‐weekly dual therapy: A 24‐week randomized, placebo‐controlled, phase <scp>II</scp> study examining effects on body weight and prediabetes in obese adults without diabetes

Per Lundkvist, C. David Sjöström, Sam Amini et al. · Diabetes Obesity and Metabolism · 2016 · 107 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: <scp>S</scp> ustained reductions in body weight, glycaemia and blood pressure over 1 year

Per Lundkvist, Maria J. Pereira, Petros Katsogiannos et al. · Diabetes Obesity and Metabolism · 2017 · 73 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Early Changes in Adipose Tissue Morphology, Gene Expression, and Metabolism After RYGB in Patients With Obesity and T2D

Petros Katsogiannos, Prasad G. Kamble, Gretha J. Boersma et al. · The Journal of Clinical Endocrinology & Metabolism · 2019 · 34 citations · Full text

Medicine, Endocrinology, Surgery +17